Open Access

Exploring predictive molecules of acute adverse events in response to volumetric‑modulated arc therapy for prostate cancer using urinary metabolites

  • Authors:
    • Hideki Obara
    • Yota Tatara
    • Satoru Monzen
    • Sho Murakami
    • Hiroki Yamamoto
    • Naoki Kimura
    • Masashi Suzuki
    • Fumio Komai
    • Masataka Narita
    • Yoshiomi Hatayama
    • Masahiko Aoki
  • View Affiliations

  • Published online on: July 9, 2024     https://doi.org/10.3892/mco.2024.2760
  • Article Number: 62
  • Copyright: © Obara et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Volumetric‑modulated arc therapy (VMAT) is a radiotherapy technique used to treat patients with localized prostate cancer, which is frequently associated with acute adverse events (AEs) that can affect subsequent treatment. Notably, the radiation dose of VMAT can be tailored to each patient. In the present study, a retrospective analysis was performed to predict acute AEs in response to a therapeutic high radiation dose rate based on urinary metabolomic molecules, which are easily collected as noninvasive biosamples. Urine samples from 11 patients with prostate cancer who were treated with VMAT (76 Gy/38 fractions) were collected. The study found that seven patients (~64%) exhibited genitourinary toxicity (Grade 1) and four patients had no AEs. A total of 630 urinary metabolites were then analyzed using a mass spectrometer (QTRAP6500+; AB SCIEX), and 234 relevant molecules for biological and clinical applications were extracted from the absolute quantified metabolite values using the MetaboINDICATOR tool. In the Grade 1 acute AE group, there was a significant negative correlation (rs=‑0.297, P<0.05) between the number of VMAT fractions and total phospholipase A2 activity in the urine. Additionally, patients with Grade 1 AEs exhibited a decrease in PC aa C40:1, a phospholipid. These findings suggested that specific lipids found in urinary metabolites may serve as predictive biomarkers for acute AEs in response to external radiotherapy.
View Figures
View References

Related Articles

Journal Cover

September-2024
Volume 21 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Obara H, Tatara Y, Monzen S, Murakami S, Yamamoto H, Kimura N, Suzuki M, Komai F, Narita M, Hatayama Y, Hatayama Y, et al: Exploring predictive molecules of acute adverse events in response to volumetric‑modulated arc therapy for prostate cancer using urinary metabolites. Mol Clin Oncol 21: 62, 2024.
APA
Obara, H., Tatara, Y., Monzen, S., Murakami, S., Yamamoto, H., Kimura, N. ... Aoki, M. (2024). Exploring predictive molecules of acute adverse events in response to volumetric‑modulated arc therapy for prostate cancer using urinary metabolites. Molecular and Clinical Oncology, 21, 62. https://doi.org/10.3892/mco.2024.2760
MLA
Obara, H., Tatara, Y., Monzen, S., Murakami, S., Yamamoto, H., Kimura, N., Suzuki, M., Komai, F., Narita, M., Hatayama, Y., Aoki, M."Exploring predictive molecules of acute adverse events in response to volumetric‑modulated arc therapy for prostate cancer using urinary metabolites". Molecular and Clinical Oncology 21.3 (2024): 62.
Chicago
Obara, H., Tatara, Y., Monzen, S., Murakami, S., Yamamoto, H., Kimura, N., Suzuki, M., Komai, F., Narita, M., Hatayama, Y., Aoki, M."Exploring predictive molecules of acute adverse events in response to volumetric‑modulated arc therapy for prostate cancer using urinary metabolites". Molecular and Clinical Oncology 21, no. 3 (2024): 62. https://doi.org/10.3892/mco.2024.2760